US 12,454,529 B2
Piperazine cyclic ureas
Yaning Su, Beijing (CN); Zhaolan Zhang, Beijing (CN); Zhiyuan Zhang, San Diego, CA (US); and Yanping Xu, Beijing (CN)
Assigned to SIRONAX LTD., Grand Cayman (KY)
Appl. No. 17/998,546
Filed by SIRONAX LTD., Grand Cayman (KY)
PCT Filed May 20, 2021, PCT No. PCT/CN2021/094993
§ 371(c)(1), (2) Date Nov. 11, 2022,
PCT Pub. No. WO2021/233397, PCT Pub. Date Nov. 25, 2021.
Claims priority of application No. PCT/CN2020/091436 (WO), filed on May 20, 2020.
Prior Publication US 2023/0203019 A1, Jun. 29, 2023
Int. Cl. C07D 403/14 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 487/04 (2006.01)
CPC C07D 403/14 (2013.01) [C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 487/04 (2013.01)] 28 Claims
 
1. A compound of formula Ia:

OG Complex Work Unit Chemistry
R1 is C6 aryl comprising 0 or 1 N heteroatoms or C5 aryl comprising 1 or 2 N heteroatoms and an O or S heteroatom, wherein the C5 aryl and C6 aryl are optionally substituted with halogen, CN, or C1 to C3 alkyl;
R2 is C6 aryl comprising 0, 1 or 2 N or 3N heteroatoms or C5 aryl comprising 1 or 2 N heteroatoms and an O or S heteroatom, wherein the C5 aryl and C6 aryl are optionally substituted with halogen, CN, C1 to C3 alkoxy, or C1 to C3 alkyl optionally substituted with OH;
R3 is C5 to C8 aryl comprising 1, 2, 3 or 4 N heteroatoms, or 1 or 2 N heteroatoms and an O or S heteroatom, substituted with 0-3 substituents selected from halide, optionally-substituted N, S or O, and optionally-substituted hydrocarbyl;
or a salt, hydrate or stereoisomer thereof.